Rafael Amado - 12 Mar 2025 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
12 Mar 2025
Net transactions value
$0
Form type
4
Filing time
14 Mar 2025, 17:14:05 UTC
Previous filing
08 Jan 2025
Next filing
19 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Award $0 +65,523 $0.000000 65,523 12 Mar 2025 American Depositary Shares 65,523 $35.55 Direct F1, F2
transaction ZLAB Restricted Share Units Award $0 +21,294 $0.000000 21,294 12 Mar 2025 American Depositary Shares 21,294 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 The option vests in equal annual installments over four years beginning on 03/12/2026, the first anniversary of the date of grant, subject to continuous service.
F3 Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS.
F4 The RSUs vest in equal annual installments over four years beginning on 03/12/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Remarks:

President, Head of Global Oncology Research and Development